Movatec (Meloxicam)

Meloxicam works by reversibly inhibiting cyclooxygenase enzymes, especially COX‑2, which reduces the synthesis of prostaglandins—key mediators of inflammation, pain, and fever. By lowering prostaglandin levels at sites of inflammation, it alleviates swelling and discomfort.

The specific dose of Movatec is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other individual factors. The healthcare provider will select the appropriate amount and frequency in accordance with approved labeling and clinical guidelines.

The safety of meloxicam during pregnancy and lactation has not been established; it is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or nursing should discuss alternatives with their healthcare provider.

To request Movatec, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Compared with non‑selective NSAIDs, meloxicam shows a higher preference for COX‑2 inhibition, which may reduce gastrointestinal side‑effects while still providing effective analgesia. However, it shares similar cardiovascular and renal risk profiles, and choice of therapy should consider individual patient risk factors and clinical response.

Movatec should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and light. Do not freeze the product. Ensure the vial is kept upright and inspected for particulate matter before administration.

Movatec is supplied as a sterile solution for intramuscular injection. A qualified healthcare professional administers the dose into a suitable muscle, typically the gluteal or deltoid region, following aseptic technique and observing recommended injection volume limits.

The most serious adverse events associated with meloxicam include gastrointestinal ulceration or bleeding, severe hypersensitivity reactions such as Stevens‑Johnson syndrome or anaphylaxis, hepatic injury, renal impairment, and increased risk of cardiovascular thrombotic events. Patients should be instructed to seek immediate medical attention if they experience signs of these conditions.

Movatec is contraindicated in patients with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe renal or hepatic impairment, and in individuals with established cardiovascular disease where NSAID use is discouraged. Caution is also advised in the elderly and in patients taking anticoagulants.